By Rachael Rettner, Senior Writer
Published: 01/15/2014 05:05 PM EST on LiveScience
A new drug appears to combat the virus that causes genital herpes, suggesting it could one day be used as a treatment for people with the condition, according to a new study.
In the study, the drug pritelivir reduced the replication of herpes simplex virus type 2 (which causes genital herpes) in patients with the condition, as well as the number of days patients experienced genital lesions.
Those who took 75 milligrams of the drug each day for about a month experienced viral shedding (which indicates the virus is active and replicating in the body) on just 2.1 percent of days, compared to 16.6 percent of days in those who took a placebo. [Quiz: Test Your STD Smarts]
And those who took pritelivir at this dose experienced genital lesions on just 1.2 percent of days, compared with 9 percent of days for those who took a placebo.
More studies are needed to further assess the effectiveness of pritelivir, and compare it with existing drugs for genital herpes, the researchers said.
The new findings are good news, said Dr. Richard Whitley, a professor of pediatric infectious diseases at the University of Alabama at Birmingham, who was not involved in the study. "This is the first drug in 30 years that has a different mechanism of action" than existing drugs, Whitley said.
New treatments for genital herpes are needed because current drugs do not work well for certain complications of genital herpes, including brain infections, and infections that can occur in babies who contract the virus at birth, Whitley said.
And while current drugs reduce symptoms, they don't eliminate them, and they only partly reduce the risk of spreading herpes through sexual activity, said study researcher Dr. Anna Wald, a professor of allergy and infectious diseases at the University of Washington School of Public Health in Seattle.
"There's clearly room for improvement" with genital herpes drugs, Wald said.
Wald noted that older drugs are active only in cells that are infected with the herpes virus.
"That’s one of the reason why the drugs are so safe. But [it] may limit the efficacy of the drug," Wald said. On the other hand, pritelivir is active even in cells unaffected by the virus.
In rare cases, people with immune system problems have developed resistance to the current drugs used to treat herpes. Alternative drugs for genital herpes could offer a solution to this problem, Whitley said.
No serious side effects linked to pritelivir were seen in the current study, which looked at 156 people.
However, in May last year, the Food and Drug Administration placed development of pritelivir on hold because high doses of the drug given to monkeys were linked with toxic effects. Researchers are investigating the cause of these toxic effects.
Whitley said he suspects the hold will be lifted, and studies in people can continue.
The study was funded by AiCuris, the pharmaceutical company that is developing pritelivir.
Follow Rachael Rettner @RachaelRettner. Follow LiveScience @livescience, Facebook & Google+. Original article on LiveScience.
Copyright 2014 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. ]]>
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.